Shots:
The company reported the extension data from the pivotal trial to evaluate Omnipod 5 automated insulin delivery system in children aged 2 through 5.9yrs. with type 1 diabetes for 12mos.
The results showed an improvement in time in range (67.6% after 12 mos. of Omnipod 5 use vs 57.2% during standard therapy) and 68.1% during 3mos. pivotal trial; avg. HbA1c (9% vs 7.4% & 6.9%) & was shown to be safe and effective in the 3mos. of trial, percent time in hypoglycemia (<70 mg/dL) was reduced over standard therapy with the median (1.9% vs 2.2% & 1.9%)
Additionally, no episodes of DKA or severe hypoglycemia were reported. Omnipod 5 is the first tubeless, wearable AID system in the US
Ref: Businesswire | Image: Insulet
